Altesa BioSciences Unveils Promising Data on Vapendavir at ICAR 2026 Altesa BioSciences to present groundbreaking data on vapendavir, showing its effectiveness against rhinovirus infections in respiratory patients at ICAR 2026.

Altesa BioSciences Unveils Promising Data on Vapendavir at ICAR 2026 #United_States #College_Park #Altesa_BioSciences #Vapendavir #Rhinovirus

Altesa BioSciences Secures $75 Million to Revolutionize COPD Treatments with New Funding Altesa BioSciences recently completed an oversubscribed $75 million Series B financing to improve treatments for chronic lung diseases like COPD, enhancing patient quality of life.

Altesa BioSciences Secures $75 Million to Revolutionize COPD Treatments with New Funding #United_States #Atlanta #COPD #Altesa_BioSciences #Rhinovirus

Altesa BioSciences Unveils Promising Results for Vapendavir in COPD Patients with Rhinovirus Infections Altesa BioSciences reports significant findings on vapendavir, showing it can reduce virus load in COPD patients and enhance their quality of life.

Altesa BioSciences Unveils Promising Results for Vapendavir in COPD Patients with Rhinovirus Infections #Netherlands #Amsterdam #COPD #Altesa_BioSciences #Vapendavir

Altesa BioSciences Partners with bioMérieux for Pioneering COPD Clinical Trial Altesa BioSciences collaborates with bioMérieux to launch a Phase 2B clinical trial for COPD using innovative diagnostics and antiviral treatment.

Altesa BioSciences Partners with bioMérieux for Pioneering COPD Clinical Trial #United_States #Atlanta #bioMérieux #Altesa_BioSciences #COPD_Clinical_Trial

Altesa BioSciences Unleashes New Hope for COPD at ERS 2025 Congress Altesa BioSciences unveils promising new treatment for COPD at the ERS 2025. Vapendavir shows significant benefits in symptoms, offering hope to many.

Altesa BioSciences Unleashes New Hope for COPD at ERS 2025 Congress #United_States #Atlanta #Altesa_BioSciences #Vapendavir #COPD_Treatment

Congressional BIOTech Caucus: A New Era for Innovative Medical Solutions Former FDA Commissioner Brett P. Giroir praises the new Congressional BIOTech Caucus for its potential to transform chronic care solutions and drive innovative biotech advancements.

Congressional BIOTech Caucus: A New Era for Innovative Medical Solutions #United_States #Atlanta #Altesa_BioSciences #Brett_Giroir #BIOTech_Caucus

Former FDA Official Champions Accelerated Drug Review for Innovative Health Solutions Brett Giroir, a former senior official at the FDA, praises a new drug review initiative that aims to expedite innovative therapies, benefiting public health.

Former FDA Official Champions Accelerated Drug Review for Innovative Health Solutions #USA #Atlanta #FDA #Altesa_BioSciences #Brett_Giroir

Altesa BioSciences Welcomes Dr. Katharine Knobil as New Chief Medical Officer Altesa BioSciences has appointed Dr. Katharine Knobil as Chief Medical Officer, aiming to advance treatments for viral infections impacting vulnerable populations.

Altesa BioSciences Welcomes Dr. Katharine Knobil as New Chief Medical Officer #United_States #College_Park #Altesa_BioSciences #Vapendavir #Katharine_Knobil

Altesa BioSciences Advances COPD Treatment with FDA IND Clearance for Vapendavir Altesa BioSciences has received FDA clearance for its Investigational New Drug application for Vapendavir, targeting rhinovirus infections in COPD patients.

Altesa BioSciences Advances COPD Treatment with FDA IND Clearance for Vapendavir #United_States #College_Park #COPD #Altesa_BioSciences #Vapendavir